Abstract
Optimization of Biologic Therapy Implementation for the Treatment of Chronic Obstructive Pulmonary Disease in Older Adults
Margaret Connolly, MD
COPD is a debilitating condition affecting millions worldwide, impacting older adults disproportionately. Recently, biologic therapies including dupilumab and mepolizumab have been approved for treatment of Eosinophilic phenotype COPD. These tailored therapies target the inflammatory cascade, reducing inflammation contributing to exacerbations and poor symptom control. Both dupilumab and mepolizumab have been shown to significantly reduce COPD exacerbation rates in patients with refractory COPD symptoms and history of exacerbations. Unfortunately, historically there have been significant delays in the adoption of such new therapies , with consistent practice change taking an average of 17 years to reach eligible patients. These delays can be prevented through better understanding of factors that drive gaps in evidence-based care implementation.
This project will generate essential knowledge of existing gaps in utilization of biologic therapies for treatment of COPD. The project will evaluate overall cost? and cost effectiveness of using biologic therapies for treatment of COPD as well as costs associated with existing gaps in access,, identifying target areas for intervention designed to improve consistent implementation. This project aims to bridge the gap between the approval and widespread use of biologic therapies for COPD by identifying and implementing effective outreach strategies. By accelerating the adoption of this new therapy, we can improve patient outcomes and reduce the burden of COPD particularly among older adults.